6446 Share Price Performance
NT$559.00
-6.00 (-1.06%)
Price NT$559.00
Share PriceNT$559.00
PharmaEssentia Corporation's (TWSE:6446) 27% Dip In Price Shows Sentiment Is Matching Revenues
Mar 14
PharmaEssentia Corporation Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 6 Fair Values set on narratives written by author
6446 Community Narratives
There are no narratives available yet.
Recent 6446 News & Updates
PharmaEssentia Corporation Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 10.95
- Gross Margin
- 88.16%
- Net Profit Margin
- 32.06%
- Debt/Equity Ratio
- 0.2%
PharmaEssentia Corporation Competitors
Snowflake Analysis
About 6446
- Founded
- 1990
- Employees
- n/a
- CEO
- WebsiteView website
PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutropenia. In addition, it focuses on the drug research and development programs in the areas of hematology, infectious disease, and oncology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Taiwanese Market Performance
- 7 Days: 4.4%
- 3 Months: 18.2%
- 1 Year: 18.0%
- Year to Date: 16.2%
Over the last 7 days, the market has risen 4.4%, driven by gains of 6.3% in the Information Technology sector. The market is up 18% over the last 12 months. As for the next few years, earnings are expected to grow by 18% per annum. Market details ›